Naim Alkhouri, MD, is Chief Academic Officer at Summit Clinical Research and the Director of the Steatotic Liver Disease Program at the Clinical Research Institute of Ohio.

WAYFIND: Exploring Combination Therapy for MASH Cirrhosis, With Naim Alkhouri, MD

While cirrhosis has traditionally been viewed as an irreversible stage of chronic liver disease, emerging data from pharmacologic trials have begun to challenge that notion. Among these, the phase 2 WAYFIND trial has drawn considerable attention for testing a novel combination approach in patients with biopsy-proven 

metabolic dysfunction-associated steatohepatitis (MASH)

 cirrhosis, with results recently presented at the 

American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2025

In the past 2 years, the MASH treatment landscape has seen the addition of the first 2 US Food and Drug Administration approved therapies in the form of resmetirom and semaglutide. However, neither agent indicated for patients with cirrhotic MASH, representing a substantial unmet need for this population.

Seeking to address this therapeutic gap, the Naim Alkhouri, MD, chief academic officer of Summit Clinical Research and director of the Steatotic Liver Program at North Shore Gastroenterology, and investigators on the WAYFIND trial assessed the efficacy and safety of semaglutide alone and in fixed-dose combination with cilofexor and firsocostat in patients with compensated cirrhosis due to MASH. The multicenter, double-blind, phase 2b study randomly assigned adults with biopsy-proven F4C due to MASH in a 3:3:3:2 ratio to receive semaglutide 2.4 mg/week + cilofexor 30 mg/firsocostat 20 mg/day, semaglutide 2.4 mg/week, cilofexor 30 mg/firsocostat 20 mg/day, or placebo for 72 weeks.

The primary endpoint was the proportion of patients with fibrosis improvement without MASH worsening at week 72 with semaglutdie+cilofexor/firsocostat versus placebo. Secondary (with prespecified testing hierarchy) and exploratory efficacy endpoints and safety were also assessed.

Of 457 patients who were randomized in the trial, 453 had ≥1 study drug dose. Their mean age was 62 years, 68.2% had type 2 diabetes, and mean platelets were 191×109/L.

Investigators noted there was no significant difference in the proportions of patients with fibrosis improvement without MASH worsening at week 72 with semaglutide+cilofexor/firsocostat versus placebo (13.7% vs 8.3%; 

= .2289). However, fibrosis improvement was observed with cilofexor/firsocostat versus placebo (20.3% vs 8.3%; 

Further analysis with PathAI analysis revealed a difference with semaglutide+cilofexor/firsocostat versus placebo (21.0% vs 6.0%; 

= .0011). Investigators noted MASH resolution was greater with semaglutide+cilofexor/firsocostat versus cilofexor/firsocostat or placebo and with semaglutide versus placebo in both pathologist and PathAI analyses.

The most frequent adverse events (AEs) occurring more often with semaglutide+cilofexor/firsocostat versus placebo were nausea (47.6% vs 22.6%), diarrhea (27.4% vs 17.9%), constipation (24.2% vs 8.3%), vomiting (21.8% vs 7.1%), and decreased appetite (15.3% vs 6.0%). Serious AEs and AEs leading to study discontinuation were similar across all groups. A single death occurred in each of the semaglutide and cilofexor/firsocostat groups.

“In my opinion, these data speak to the potential of reversing cirrhosis, [which has a] very high unmet need, and although we did not hit the primary endpoint, I think we see several secondary endpoints that improved with these treatments,” Alkhouri said.

Editors’ note: Alkhouri reports relevant disclosures with Altimmune, Madrigal Pharmaceuticals, Merck, Novo Nordisk, Rivus, Takeda, and others.

Alkhouri N, Kowdley K, Lawitz E, et al. A randomized, placebo-controlled, phase 2 study of the safety and efficacy of combination treatment with semaglutide, cilofexor and firsocostat in patients with compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis (WAYFIND). Presented at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2025. Washington, DC. November 7-11, 2025.

Brooks A. Resmetirom (Rezdiffra) Receives Historic FDA Approval for Noncirrhotic NASH. HCPLive. March 14, 2024. Accessed November 18, 2025. 

https://www.hcplive.com/view/resmetirom-rezdiffra-receives-historic-fda-approval-for-noncirrhotic-nash

Brooks A. FDA Approves Semaglutide (Wegovy) Injection 2.4 mg for Noncirrhotic MASH. HCPLive. August 15, 2025. Accessed November 18, 2025. 

https://www.hcplive.com/view/fda-approves-semaglutide-wegovy-injection-2-4-mg-for-noncirrhotic-mash

Videos

Alkhouri explains findings from the phase 2 WAYFIND trial suggesting the potential of semaglutide and cilofexor/firsocostat for MASH cirrhosis.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Hepatology

MASH / MASLD

The HCPLive MASH & MASLD page is a comprehensive resource for clinical news and insights on metabolic dysfunction-associated steatotic liver disease and steatohepatitis. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for fatty liver disease, steatohepatitis, and more.

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

Image Credit: US Food and Drug Administration

Announced by Arrowhead Pharmaceuticals on November 18, 2025, the US Food and Drug Administration has approved plozasiran under the brand name REDEMPLO for the reduction of triglycerides in adult patients with familial chylomicronemia syndrome (FCS).

"Today's approval marks a pivotal moment for people living with familial chylomicronemia syndrome and the physicians who support them," Lindsey Sutton Bryan, co-founder and co-president of the FCS Foundation, said in a statement. "Because FCS symptoms are mostly invisible, this community historically has been often overlooked and misunderstood, making their journey to effective treatment especially difficult."

Plozasiran, a first-in-class investigational RNA interference therapeutic, is designed to reduce apoC-III production. ApoC-III is a major component of triglyceride-rich lipoproteins (TRLs) and a regulator of triglyceride metabolism, as it increases triglyceride levels in the blood by preventing breakdown of TRLs by lipoprotein lipase and the uptake of TRL remnants by hepatic receptors in the liver.

The FDA accepted plozasiran’s New Drug Application (NDA) on January 17, 2025, based on results from the PALISADE phase 3 trial. The application also included supportive evidence from the phase 2 SUMMIT program. PALISADE met its primary endpoint and all multiplicity-controlled key secondary endpoints, including statistically significant reductions in triglycerides, apoC-III, and acute pancreatitis incidence.

Investigators in the PALISADE trial included patients who had a fasting triglyceride level ≥880 mg/dL at screening refractory to standard lipid lowering therapy, as well as a diagnosis of FCS, who were willing to follow dietary counseling based on investigator judgment and local standard of care. Patients were excluded if they were using or had used any hepatocyte-targeted siRNA or antisense oligonucleotide molecules within the last 365 days, if they had diabetes mellitus newly diagnosed or active pancreatitis within 12 weeks before screening, if they had uncontrolled hypertension, or if they had New York Heart Association Class II, III, or IV heart failure, among other criteria.

A total of 75 participants were enrolled in PALISADE, and were randomly assigned to either 25 mg plozasiran, 50 mg plozasiran, or matching placebo, all of which were administered once every 3 months. The primary endpoint was the percent change from baseline in fasting triglycerides at month 10. Secondary endpoints included an average of the percent change from baseline in fasting triglycerides at months 10 and 12, as well as percent changes in apoC-III and non-HDL-C at months 10 and 12.

Ultimately, patients in the 25 mg arm saw a median change in triglycerides from baseline of 80% and an 83% decreased risk of acute pancreatitis versus placebo in the pooled plozasiran 25 mg and 50 mg group. Investigators also reported a favorable tolerability profile throughout the trial. The 25 mg dose also saw only the adverse events of abdominal pain, nasopharyngitis, nausea, and COVID-19.

"The FDA approval of REDEMPLO is a transformational milestone for Arrowhead. This is a proud moment for all those involved in the discovery and development process and represents new hope for the estimated 6500 people in the US living with genetic or clinical FCS," Christopher Anzalone, PhD, president and chief executive officer at Arrowhead Pharmaceuticals, said in a statement.

In a press release, Arrowhead Pharmaceuticals has confirmed that plozasiran will be available in the US before the end of 2025.

Anzalone V. Arrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS). BusinessWire. November 18, 2025. Accessed November 18, 2025. 

https://www.businesswire.com/news/home/20251112678197/en/Arrowhead-Pharmaceuticals-Announces-FDA-Approval-of-REDEMPLO-plozasiran-to-Reduce-Triglycerides-in-Adults-with-Familial-Chylomicronemia-Syndrome-FCS

Anzalone V. Arrowhead Pharmaceuticals Announces Acceptance of New Drug Application by U.S. FDA of Plozasiran for the Treatment of Familial Chylomicronemia Syndrome. Arrowhead Pharmaceuticals Newsroom. January 17, 2025. Accessed November 17, 2025. 

https://arrowheadpharma.com/news-press/arrowhead-pharmaceuticals-announces-acceptance-of-new-drug-application-by-u-s-fda-of-plozasiran-for-the-treatment-of-familial-chylomicronemia-syndrome/

Arrowhead Pharmaceuticals. Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS) (PALISADE). ClinicalTrials.gov Identifier: NCT05089084. Updated April 30, 2025. Accessed November 17, 2025. 

https://clinicaltrials.gov/study/NCT05089084

Articles

The FDA has approved plozasiran, branded as REDEMPLO, for reducing triglycerides in adults with familial chylomicronemia syndrome (FCS). This RNA interference therapeutic targets apoC-III, a key regulator of triglyceride metabolism. Approval was based on the PALISADE phase 3 trial, which demonstrated significant reductions in triglycerides and acute pancreatitis incidence. The trial included patients with high triglyceride levels unresponsive to standard therapy. Plozasiran showed a favorable safety profile, with minimal adverse events. Arrowhead Pharmaceuticals plans to make plozasiran available in the US by the end of 2025.

The FDA has approved RNA interference therapeutic plozasiran for the treatment of familial chylomicronemia syndrome.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Dyslipidemia

FDA News

FDA Approves Plozasiran for Adults With Familial Chylomicronemia Syndrome

Juan Badimon, PhD, is a professor of medicine and the director of the Atherothrombosis Research Unit at the Cardiovascular Institute of the Icahn School of Medicine at Mount Sinai.

SOTA-P-CARDIA: Sotagliflozin Exhibits Antithrombotic Effects in Patients with HFpEF, With Juan Badimon, PhD

Sotagliflozin treatment resulted in a statistically significant improvement in left ventricular mass, diastolic function, capacity for the 6-minute walk test, and Kansas City Cardiomyopathy Questionnaire (KCCQ) measurements in patients with 

heart failure with preserved ejection fraction (HFpEF)

 without diabetes, according to results from the SOTA-P-CARDIA study.

American Heart Association’s Scientific Sessions 2025

 in New Orleans, Louisiana, by Juan Badimon, PhD, professor of medicine and director of the atherothrombosis research unit at the Cardiovascular Institute at the Icahn School of Medicine at Mount Sinai. Although the trial reached statistical significance in several measures, it failed to achieve significance in peak VO2 improvement, despite producing a notable improvement after sotagliflozin treatment.

Sotagliflozin is an oral combination SGLT2 and SGLT1 inhibitor, which simultaneously monitors glucose and sodium reabsorption in the kidney and the gastrointestinal tract. It has been studied in patients with HF, diabetes, and 

, and is currently under investigation for 

The previous SOLOIST and SCORED trials investigated sotagliflozin’s efficacy in patients with 

 hospitalized for worsening HF and patients with T2DM and chronic kidney disease, respectively. Both trials achieved their endpoints and saw effects on HF irrespective of left ventricular ejection fraction. However, despite these outcomes, neither trial established sotagliflozin’s mechanism of action.

 sat down with Badimon to discuss the implications of these data and next steps for SGLT2 inhibitor research in patients with HF.

“One of the things to take into account is that the SOLOIST and the SCORED trials enrolled exclusively diabetic patients,” Badimon told 

. “So, one of the objectives that we wanted to investigate is whether we could expand the benefits seen in the SOLOIST and SCORED trials to a non-diabetic HFpEF population.”

For enrollment in the SOTA-P-CARDIA study, patients were required to be ambulatory, exhibit no diabetes as confirmed by HbA1c <6.5%, fasting serum glucose <126 mg/dL, and review of concomitant medications and medical history, as well as having a diagnosis of heart failure (HF), LVEF >50%, and being on medical therapy for HF for ≥4 weeks prior to screening. Patients with 

and 2 diabetes, acute coronary syndrome or cardiac surgery within the last week, acute decompensated HF or hospitalized HF within 1 month, or who had been receiving SGLT inhibitors 3 months prior to randomization were excluded.

A total of 88 patients were included, with notable racial diversity and of whom 70% were female. Patients were randomly assigned in blocks of 4 to either sotagliflozin or placebo, administered daily over 6 months. The primary outcome was change in left ventricular mass at 6 months compared to baseline, while secondary endpoints included changes in left ventricular end-systolic volume (LVESV) at 6 months, changes in left ventricular end-diastolic volume (LVEDV) at 6 months, changes in extracellular volume at 6 months, changes in peak oxygen consumption at 6 months, changes in 6-minute walk test results at 6 months, and changes in KCCQ results at 6 months, among other factors.

Ultimately, investigators found that 6-month satagliflozin administration resulted in improvements in left ventricular mass, diastolic function, 6-minute walk test, and KCCQ measurements. Badimon spoke with 

 on the results of the trial, as well as the next steps for sotagliflozin research in patients with HFpEF.

“I think we need to start getting familiar with the dual SGLT-2/SGLT-1 inhibitors because they have similar effects to the specific SGLT-2 inhibitor; they have this effect on reducing atherothrombotic events,” Badimon said. “Theoretically, inhibiting SGL-1 and -2 seems to offer the better choice. But again, we need to be patient; we have more data coming.”

DeFrancesco L. Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Ejection Fraction Heart Failure (HFpEF) without Diabetes Presented at American Heart Association (AHA) Annual Scientific Sessions 2025. Lexicon Pharmaceuticals. November 8, 2025. Accessed November 18, 2025. 

https://investors.lexpharma.com/news-releases/news-release-details/clinical-data-demonstrating-efficacy-sotagliflozin-preserved

Badimon J. Sotagliflozin in Heart Failure with Preserved Ejection Fraction (HFpEF) Patients. ClinicalTrials.gov Identifier: NCT05562063. Updated July 18, 2025. Accessed November 18, 2025. 

https://www.clinicaltrials.gov/study/NCT05562063

Badimon J, Requena JA, Santos-Gallego C, et al. SOTA-P-CARDIA Trial (ATRU-V): A Randomized Trial of Sotagliflozin in HFpEF patients without diabetes. Abstract presented at the American Heart Association’s Scientific Sessions 2025. New Orleans, Louisiana. November 8-10, 2025.

Badimon explains the impact of sotagliflozin’s improvements in left ventricular mass, diastolic function, and 6-minute walk test results in patients without diabetes.

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Importance of Addressing the Psychosocial Burden of HAE Among Children, With Raffi Tachdjian, MD

 is often approached through symptom control and attack prevention. However, emerging data highlight another equally important facet for pediatric patients: the psychosocial toll.

2025 American College of Allergy, Asthma, & Immunology (ACAAI) Annual Scientific Meeting

 in Orlando, Florida, Raffi Tachdjian, MD, MPH, from UCLA Health, presented on a recent study examining the psychosocial impact of HAE on young patients, caregivers, and clinicians.

“When we think of HAE, we've always been focused on the grown-ups,” Tachdjian told 

 during the meeting. “When we think of the pediatric age category, these kids often don't know how to express an attack because they don't have the experience or descriptions, and it could be a novel attack. We see a lot of negativity surrounding it.”

He observed drops in communication and attendance among children with HAE. Children with HAE often report missing both school and after-school activities. This absence raises concerns for many parents and healthcare professionals.

“That burden is higher than we thought it was,” Tachdjian continued. “This study is opening our eyes to that. It's an unmet need.”

These challenges evolve as patients age. Older adolescents begin to experience academic underachievement and ongoing school absences.

Tachdjian emphasized the importance of individualized, multi-pronged strategies. Effective interventions may include counseling, more frequent follow-up with healthcare providers, expanded parent-child communication, or increased peer and social support. He stressed that there is no single formula; instead, shared decision-making and exploration of each patient’s unique fears, such as anticipatory anxiety about future attacks, are critical for reducing distress.

Validated tools such as the Angioedema Control Test and the Angioedema Quality of Life instrument already help clinicians assess psychosocial burden, but new tools and parameters are in development. These could further guide care teams in identifying barriers early and tailoring support to improve long-term outcomes.

“I'd like to highlight that this is a big step,” Tachdjian said. “We're not by any means done, but it's a big step towards pushing this psychosocial aspect of a genetic condition that has other issues that come with it, such as fear, anxiety, depression, lack of communication, social skills, isolation, all things that we could fall into as a trap. As a healthcare team, we want to ensure that we're doing our best to prevent these negatives and really boost the positives.”

Relevant disclosures for Tachdjian include GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc., BioCryst US Sales Co., LLC, Grifols USA, LLC, Takeda Pharmaceuticals U.S.A., Inc., CSL Behring, Pharming Healthcare, Inc., AstraZeneca Pharmaceuticals LP, GlaxoSmithKline, LLC., Dermavant Sciences, Inc., and X4 Pharmaceuticals, Inc.

Tachdjian, R. Psychosocial Impact of Hereditary Angioedema on Young Patients and Their Caregivers. Presented at ACAAI 2025 in Orlando, Florida, from November 6 – 10.

New qualitative findings reveal the underrecognized psychosocial burdens facing children with HAE and the unmet needs shaping their care.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

Credit: International Symposium of IgA Nephropathy

New research shows RemeGen’s telitacicept exhibited efficacy and a favorable safety profile in adults with 

A 39-week phase 3 multicenter, randomized, double-blind, 2-part study examined telitacicept’s impact on urine protein creatinine ratio (UPCR), CD19+ B-cell count, immunoglobulin levels (IgG, IgA, and IgM), and estimated glomerular filtration rate (eGFR).

A novel fusion protein and B-cell modulating biologic, telitacicept, dually targets and neutralizes B-lymphocyte stimulator (BLyS) and A proliferation-inducing ligand (APRIL), 2 immune-system signalling proteins implicated in the production of pathogenic galactose-deficient IgA1.

“Telitacicept delivered statistically significant deep, sustained, and clinically meaningful reductions in proteinuria with stabilization of kidney function and a favorable safety profile. An objective endpoint like 24h-UPCR validates the therapeutic effect of dual BAFF/APRIL inhibition,” said Jean-Paul Kress, MD, chief executive officer and chairman of the board at Vor Bio in a statement from the company. “With this Phase 3 success in IgAN, telitacicept has provided additional clinical evidence supporting its mechanism in yet another indication, reinforcing our confidence in its potential as a foundational therapy for B-cell mediated diseases.”

In stage A, patients were randomly assigned in a 1:1 ratio to receive subcutaneous telitacicept 240mg or placebo once weekly for 39 weeks, with a primary endpoint of change from baseline in 24-hour UPCR. Other endpoints assessed were kidney function, measured by eGFR, resolution of hematuria, changes in B-cell counts, and serum immunoglobulins.

Investigators reported telitacicept achieved the primary endpoint of reducing proteinuria, with a -58.9% change in 24-hour urine protein-to-creatinine ratio (24h-UPCR) compared with -8.8% for placebo (

Telitacicept also demonstrated substantial proteinuria improvements across additional measures. At week 39, the treatment group showed a 55% reduction in 24h-UPCR. A greater proportion of patients receiving telitacicept achieved thresholds associated with lower progression risk: 61% vs 19.5% achieved 24h-UPCR <0.8 g/g, 42.1% vs 7.5% achieved <0.5 g/g, and 24.5% vs 0.6% achieved <0.3 g/g.

Across secondary endpoints, kidney function remained stable with telitacicept. Investigators reported a stabilized eGFR (-0.010 mL/min/1.73 m²) in the telitacicept group, compared with a decline (-0.77 mL/min/1.73 m²) in the placebo group. The risk of ≥30% eGFR decline was lower among patients receiving telitacicept than in the placebo group (27.0%).

Investigators noted a favorable safety profile. Although treatment-emergent adverse events occurred more frequently with telitacicept (89.3%) than placebo (78.6%), most were mild or moderate. Serious adverse events occurred less often with telitacicept (2.5%) than placebo (8.2%).

The investigational recombinant fusion protein enters a 

rapidly evolving therapeutic landscape in IgAN

, where multiple B-cell–, BAFF-, and APRIL-targeted approaches are under active clinical investigation. These include 

, which is designed to interrupt the upstream biology that drives Gd-IgA1 generation in IgAN and anti-PLA2R autoantibody production in pMN, and 

, which has continued to demonstrate reductions in galactose-deficient immunoglobulin A1 along with a favorable safety profile.

Jicheng L, Liu LJ, Wang W. Efficacy and Safety of Telitacicept in Patients with IgAN: Results from Stage A of a Phase 3 Clinical Study. 

Journal of the American Society of Nephrology

Telitacicept Demonstrates Clinically Meaningful and Statistically Significant Impact on ESSDAI Compared to Placebo in Late-Breaking China Phase 3 Results in Primary Sjögren’s Disease at ACR 2025 | Vor Bio. Vor Bio. Published 2025. Accessed November 18, 2025. 

https://ir.vorbio.com/news-releases/news-release-details/telitacicept-demonstrates-clinically-meaningful-and

Telitacicept Achieved Primary Endpoint of Reducing Proteinuria in Stage A of a Phase 3 Clinical Study for IgA Nephropathy in China | Vor Bio. Vor Bio. Published 2025. Accessed November 18, 2025. 

https://ir.vorbio.com/news-releases/news-release-details/telitacicept-achieved-primary-endpoint-reducing-proteinuria

Telitacicept, a novel fusion protein, has shown efficacy and a favorable safety profile in a Phase 3 study for IgA nephropathy (IgAN). The study demonstrated significant reductions in proteinuria and stabilization of kidney function, with a notable decrease in the 24-hour urine protein-to-creatinine ratio. Telitacicept targets B-lymphocyte stimulator (BLyS) and A proliferation-inducing ligand (APRIL), crucial in IgAN pathogenesis. Despite a higher incidence of mild to moderate adverse events, serious adverse events were less frequent compared to placebo, reinforcing telitacicept's potential as a foundational therapy for B-cell mediated diseases.

Dual BLyS/APRIL inhibition with telitacicept led to significant 24h-UPCR reductions, lower progression-risk thresholds, and stable eGFR compared with placebo.


Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

IgA Nephropathy

The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.

Telitacicept Achieves Primary Endpoint in IgA Nephropathy Phase 3 Study

This November 18 episode explores early detection, diagnosis, and management of scarring alopecias and hair-care–related hair loss in patients of color.

Skin of Color Savvy: The Art and Science of Treating Patients of Color

Hosted by Skin of Color Society and produced by HCPLive, 

 delves into the latest research, clinical insights, and culturally intelligent care practices in dermatology with leading experts. 

Whether it’s groundbreaking research, practice-changing insights, or highlights from the SOCS community, this twice-monthly program provides dermatologists and care providers with expert perspectives on treating patients with skin of color.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Podcasts

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Skin of Color Savvy: Hair-Care Challenges in Dermatology With Amy McMichael, MD, and Kayla Taylor, MD

Panelists discuss how evidence from clinical studies supports the safety and effectiveness of new nonsteroidal treatments for children with AD.

Video Series

Peer Exchange

HCPLive® Peer Exchange panel discussions feature authoritative insights, opinions, and perspectives on important issues facing today's care professionals.

Roflumilast Efficacy and Safety in Pediatric AD

Linda Stein Gold, MD, is a dermatologist at Henry Ford Health. 

The experts analyze new patient and clinician survey data, revealing gaps between treatment satisfaction and practice realities.

Factoring Comorbidities into Diagnostic Workup for Psoriasis Patients 

Discussion on how patient goals, treatment experiences, and preference for oral agents shape individualized therapy plans.

Expert Perspectives on When to Discuss Psoriatic Arthritis With Patients 

Panelists discuss how low systemic absorption and simple dosing schedules improve safety, adherence, and caregiver confidence in pediatric AD care.

Systemic Absorption and Dosing in Pediatric AD

Professor of Rheumatology, Northwestern Feinberg School of Medicine

Ramsey-Goldman emphasized the importance of QoL in lupus, looking beyond disease scores.

Lupus

Rheumatology

Rheumatology condition center page is a comprehensive resource for clinical news and insights on rheumatologic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for arthritis, gout, nr-AxSpA, and more.

Fatigue, Pain, Daily Function: DZP’s Patient-Centered Impact in SLE, with Rosalind Ramsey-Goldman, MD

Ramsey-Goldman discussed the potential of NAC for treating systemic lupus erythematosus.

Proof of Concept: Targeting Mitochondrial Dysfunction in SLE With NAC, with Rosalind Ramsey-Goldman, MD

Nicholas Marston, MD, is a cardiologist and an assistant professor of medicine at Brigham and Women's Hospital.

Marston discusses the CORE and CORE2 trials, highlighting olezarsen’s success in lowering fasting triglyceride.

Olezarsen Proves Efficacy in Severe Hypertriglyceridemia, With Nicholas Marston, MD

Vinay Mehta, MD: Board-certified allergist/immunologist with Allergy & Asthma Associates of Southern California

A phase 3b study in patients with skin of color found lebrikizumab provides reliable efficacy and safety for treating moderate-to-severe AD.


Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Lebrikizumab Effectively Treats AD in Patients with Skin of Color, With Vinay Mehta, MD

Panelists examine how these emerging therapies compare with existing options and consider what their advances mean for clinicians and patients in everyday practice.

Latest News

WAYFIND: Exploring Combination Therapy for MASH Cirrhosis, With Naim Alkhouri, MD

FDA Approves Plozasiran for Adults With Familial Chylomicronemia Syndrome

SOTA-P-CARDIA: Sotagliflozin Exhibits Antithrombotic Effects in Patients with HFpEF, With Juan Badimon, PhD

Importance of Addressing the Psychosocial Burden of HAE Among Children, With Raffi Tachdjian, MD

Telitacicept Achieves Primary Endpoint in IgA Nephropathy Phase 3 Study